Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Regulatory News & FDA Approvals » PathoFinder Gets CE Mark for Second SARS-CoV-2 PCR Test

PathoFinder Gets CE Mark for Second SARS-CoV-2 PCR Test

Jun 26, 2020
|
staff reporter

NEW YORK ─ PathoFinder said this week that it has obtained the CE-IVD mark for its RealAccurate Quadruplex SARS-CoV-2 PCR kit, allowing it to be marketed in the European Union and other countries that recognize the CE mark.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Herbert Tabor Dies

The Washington Post reports that Herbert Tabor, who worked at the US National Institutes of Health for 77 years, has died at 101.

Funds to Get Vaccines

The World Bank is seeking approval for a $12 billion plan to provide low-income nations with funds to procure SARS-CoV-2 vaccines, according to Reuters.

A Number on It

Science writes that public health officials and others are debating whether cycle threshold values should be included on SARS-CoV-2 results.

Nucleic Acids Research Studies on 3D SARS-CoV-2 Structures, Human Brain Atlas, More

In Nucleic Acids Research this week: online database of SARS-CoV-2 protein structures, atlas of the human brain, and more.

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

Oct
14
Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15
Featured Webinar

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

Sponsored by
Agena Bioscience

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

What's Popular?

In Molecular Diagnostics

  1. Fluidigm Finalizes $34M NIH Contract for SARS-CoV-2 Assay Production

  2. Swift Biosciences, BillionToOne Partner to Commercialize COVID-19 Test

  3. Access Genetics Nabs Amended FDA Emergency Use Authorization for Oral Rinse SARS-CoV-2 PCR Test

  4. NIH Awards Two SBIR Grants Totaling $3.9M to Phase Genomics

  5. Abacus Diagnostica Readying Multiplex RT-PCR Test for SARS-CoV-2, Flu, RSV

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.